US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

BridgeBio Oncology Therapeutics, Inc

12.52

+0.46503.86%

Volume:671.47K

Turnover:8.37M

Market Cap:1.00B

PE:-1.21

High:12.87

Open:12.11

Low:11.78

Close:12.06

52wk High:14.87

52wk Low:8.50

Shares:79.99M

Float Shares:44.60M

Volume Ratio:5.24

T/O Rate:1.51%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-10.3075

EPS(LYR):-511.8002

ROE:--

ROA:--

PB:2.24

PE(LYR):-0.02

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

BridgeBio Oncology Therapeutics to Present at J.P. Morgan Healthcare Conference

BridgeBio Oncology Therapeutics Grants Stock Options Under New Inducement Plan

BridgeBio Oncology Price Target Maintained With a $25.00/Share by Wedbush

BridgeBio Oncology Therapeutics Launches Phase 1 Trial of BBO-10203 in Advanced Solid Tumors

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BBOT"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BBOT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBOT\",,,,,undefined,":{"symbol":"BBOT","market":"US","secType":"STK","nameCN":"BridgeBio Oncology Therapeutics, Inc","latestPrice":12.52,"timestamp":1766178000000,"preClose":12.055,"halted":0,"volume":671465,"delay":0,"floatShares":44603977,"shares":79988687,"eps":-10.307472,"marketStatus":"Pre-Mkt","change":0.465,"latestTime":"12-22 06:39:05 EST","open":12.11,"high":12.8738,"low":11.78,"amount":8371610.079735001,"amplitude":0.090734,"askPrice":13.61,"askSize":100,"bidPrice":5.01,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-10.307472,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1766413800000},"marketStatusCode":1,"adr":0,"listingDate":1707454800000,"exchange":"NASDAQ","adjPreClose":12.52,"postHourTrading":{"tag":"盘后","latestPrice":12.52,"preClose":12.52,"latestTime":"18:57 EST","volume":7821,"amount":97917.535,"timestamp":1766188653496},"volumeRatio":5.243624546359845},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBOT\",,,,,undefined,":{"symbol":"BBOT","floatShares":44603977,"roa":"--","roe":"--","lyrEps":-511.800172,"volumeRatio":5.243624546359845,"shares":79988687,"dividePrice":0,"high":12.8738,"amplitude":0.090734,"preClose":12.055,"low":11.78,"week52Low":8.5,"pbRate":"2.24","week52High":14.87,"institutionHeld":0,"latestPrice":12.52,"committee":0.333333,"eps":-10.307472,"divideRate":0,"volume":671465,"delay":0,"ttmEps":-10.307472,"open":12.11,"prevYearClose":10.5,"prevWeekClose":12.52,"prevMonthClose":12.31,"prevQuarterClose":11.58,"fiveDayClose":12.59,"twentyDayClose":12.18,"sixtyDayClose":11.82},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BBOT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-12","symbol":"BBOT","fiscalQuarterEnding":"2025/09","expectedEps":-0.41,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"post","actualEps":-1.03},{"market":"US","date":"2025-08-01","symbol":"BBOT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754020800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-05-15","symbol":"BBOT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-11-14","symbol":"BBOT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BBOT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BBOT\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4286,"buy":0.5714,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5714,"analysts":7,"updateTime":1764997200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BBOT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BBOT","date":"2025-12-19","current":-1.214653,"percent":0.930233,"low":-11.944957,"twenty":-11.080298,"median":-9.97426,"eighty":-8.826299,"high":-7.704202,"avg":-9.96727,"sd":1.078401,"marketCap":964263621},"quantilePoints":[{"date":"2025-08-22","current":-9.544109,"twenty":-10.820609,"median":-9.81087,"eighty":-9.532253,"marketCap":835109579},{"date":"2025-08-29","current":-9.336629,"twenty":-9.787158,"median":-9.514469,"eighty":-9.277349,"marketCap":816955023},{"date":"2025-09-05","current":-9.959071,"twenty":-9.864223,"median":-9.514469,"eighty":-9.247708,"marketCap":871418691},{"date":"2025-09-12","current":-10.047991,"twenty":-10.065775,"median":-9.65773,"eighty":-9.388005,"marketCap":879199215},{"date":"2025-09-19","current":-10.690193,"twenty":-10.20212,"median":-9.78123,"eighty":-9.467045,"marketCap":935391888},{"date":"2025-09-26","current":-11.678196,"twenty":-11.017222,"median":-9.944251,"eighty":-9.487793,"marketCap":1021842155},{"date":"2025-10-03","current":-11.259509,"twenty":-11.190123,"median":-10.077631,"eighty":-9.526325,"marketCap":985207072},{"date":"2025-10-10","current":-11.196152,"twenty":-11.224546,"median":-10.323455,"eighty":-9.563869,"marketCap":979663302},{"date":"2025-10-17","current":-10.3182,"twenty":-11.192532,"median":-10.372506,"eighty":-9.601414,"marketCap":902842494},{"date":"2025-10-24","current":-9.838494,"twenty":-11.156298,"median":-10.223893,"eighty":-9.601414,"marketCap":860868237},{"date":"2025-10-31","current":-10.861263,"twenty":-11.08659,"median":-10.23674,"eighty":-9.656742,"marketCap":950360520},{"date":"2025-11-07","current":-11.087539,"twenty":-11.118284,"median":-10.345353,"eighty":-9.745662,"marketCap":970159697},{"date":"2025-11-14","current":-11.205203,"twenty":-11.201583,"median":-10.472068,"eighty":-9.804136,"marketCap":980455269},{"date":"2025-11-21","current":-8.47671,"twenty":-11.192532,"median":-10.345353,"eighty":-9.572151,"marketCap":974262207},{"date":"2025-11-28","current":-8.567184,"twenty":-11.17443,"median":-10.251046,"eighty":-9.478901,"marketCap":984660736},{"date":"2025-12-05","current":-8.0313,"twenty":-11.121014,"median":-10.182434,"eighty":-9.298176,"marketCap":923069447},{"date":"2025-12-12","current":-8.936039,"twenty":-11.105583,"median":-10.084778,"eighty":-9.061365,"marketCap":1027054741},{"date":"2025-12-19","current":-8.389716,"twenty":-11.080298,"median":-9.97426,"eighty":-8.826299,"marketCap":964263621}],"updateTime":1766375106444},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BBOT\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2592916937","title":"BridgeBio Oncology Therapeutics to Present at J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2592916937","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592916937?lang=en_us&edition=fundamental","pubTime":"2025-12-17 05:05","pubTimestamp":1765919109,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology Therapeutics Inc.  will participate in a presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 5:15 p.m. PT. The event will feature a live webcast accessible on the BBOT website, with a replay available for at least 90 days following the presentation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bridgebio Oncology Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on December 16, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDL1X2nJP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0314104364.USD","BK4505","SG9999014005.SGD","LU2210149790.SGD","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU2095319765.USD","NDAQ","SG9999014021.USD","IE00B3QW5Z07.USD","SG9999014039.USD","SG9999014013.SGD","BBOT","BK4585","IE00BGHQF748.EUR","BK4112","BK4139","BBIO","LU2210150020.SGD"],"gpt_icon":0},{"id":"2590491135","title":"BridgeBio Oncology Therapeutics Grants Stock Options Under New Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2590491135","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590491135?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:05","pubTimestamp":1765487110,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology Therapeutics Inc. has awarded a new inducement grant to an employee hired in November 2025. The grant consists of non-qualified stock options to purchase 53,060 shares of BBOT common stock at an exercise price of $12.88 per share, the closing price on the grant's effective date. The options will vest 25% on the first anniversary of the employee's start date, with the remaining shares vesting in 36 equal monthly installments thereafter, contingent on continued employment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bridgebio Oncology Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on December 11, 2025, and is solely responsible for the information contained there","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL8mqGnx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00BGHQF748.EUR","SG9999014005.SGD","IE00B3QW5Z07.USD","LU0314104364.USD","BK4505","BBOT","BBIO","BK4585","SG9999014013.SGD","SG9999014039.USD","BK4588","BK4139","LU2210150020.SGD","SG9999014021.USD","LU2095319765.USD","IE00B64PRP62.GBP","IE00BKPKM429.USD","NDAQ","LU2210149790.SGD"],"gpt_icon":0},{"id":"2590351421","title":"BridgeBio Oncology Price Target Maintained With a $25.00/Share by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2590351421","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590351421?lang=en_us&edition=fundamental","pubTime":"2025-12-11 22:39","pubTimestamp":1765463940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BBOT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 11, 2025 09:39 ET (14:39 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBOT","BK4139"],"gpt_icon":0},{"id":"2590130558","title":"BridgeBio Oncology Therapeutics Launches Phase 1 Trial of BBO-10203 in Advanced Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2590130558","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590130558?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:05","pubTimestamp":1765400716,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology Therapeutics Inc. announced late-breaking preclinical data on BBO-10203, a first-in-class covalent small molecule RAS:PI3Kα breaker, at the San Antonio Breast Cancer Symposium . The preclinical data demonstrated that BBO-10203 blocks RAS-mediated activation of PI3Kα, inhibits pAKT signaling in tumor cells without inducing hyperglycemia, and shows anti-tumor activity both as monotherapy and in combination with standard therapies in breast cancer models. The company also presented information regarding the Phase 1 BREAKER-101 clinical trial , which is currently enrolling patients with locally advanced or metastatic HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer in the United States and Australia. Initial Phase 1 clinical data from the BREAKER-101 trial are expected in the first half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. Wh","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL9wdQ8p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00B64PRP62.GBP","BK4505","LU2095319765.USD","BBOT","BK4139","IE00BGHQF748.EUR","BK4112","SG9999014021.USD","LU2210150020.SGD","LU2210149790.SGD","NDAQ","IE00BKPKM429.USD","LU0314104364.USD","BK4588","IE00B3QW5Z07.USD","SG9999014005.SGD","BBIO","SG9999014013.SGD","SG9999014039.USD"],"gpt_icon":0}],"pageSize":4,"totalPage":9,"pageCount":1,"totalSize":35,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/BBOT\",params:#limit:6,delay:false,,,undefined,":[]}}